New drug duo battles tough liver cancer in Head-to-Head trial
NCT ID NCT07152769
Summary
This study aims to see if a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus standard chemotherapy works better than a different immunotherapy (sintilimab) plus the same chemo for people with advanced bile duct cancer inside the liver. It will involve 104 participants who have not had prior treatment for their advanced cancer. The main goal is to see if the new combination keeps the cancer from getting worse for a longer period.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED INTRAHEPATIC CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200062, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.